Accessibility
Bigger text
High contrast
Collaborate
Donate
Contact
English
Dansk
Ελληνικά
Back to EUPATI
About
Can I Trust the EUPATI Material?
Can I Reuse the EUPATI Material?
Toolbox User-guide
Resources
What is Meaningful Patient Engagement?
Publications
Starter kits for trainings
Webinars
Glossary
Toolbox
Collaborate
Donate
Contact
Back to EUPATI
Category - Patient engagement case studies
Sorry, nothing to display.
Related tags
Please select
Search
Sort by
Sort Results By
Relevance
Title (A-Z)
Title (Z-A)
Date (Asc)
Date (Desc)
Medicines R&D
Patient Engagement
Search the Toolbox
Advocacy
Basics of Medicine R&D
Benefit and Risk Assessment
Clinical Development / Trials
Digital Health
Drug Discovery
Health Communication
HTA
Interview
Medical Devices
Non-Clinical Studies
Patient engagement case studies
Patient Engagement Toolbox
Patient Involvement
Personalised Medicine
Pharmaceutical Development
Pharmacoepidemiology
Regulatory Affairs
Safety of Medicines
Starter Kits
Types of Medicines
Uncategorized
Webinar
Absorption
Active Ingredient
Active Pharmaceutical Ingredient
Activism
Adaptive Design
Adaptive Pathways
Adherence
ADME
Administering Medicine
Advanced Therapeutic Medicinal Products (ATMPs)
Advanced Therapies
Adverse Event (AE)
Advertising Clinical Trials
Advocacy
AIDS
Analytic Framework
Animal models
Benefit-Risk Assessment
Benefit-Risk Balance
Best Pharmaceuticals For Children Act (BPCA)
Best Practice
Bias
Bioavailability
Bioequivalence
Biologic Medicines
Biomarkers
Biomedical Research
Biosimilar Medicines
Blinding
Botanicals
Breastfeeding
Carcinogenicity
Centralised Procedure (CP)
Certificate Of Suitability (CEP)
Children
Classification
Clinical Development
Clinical Effectiveness
Clinical Studies
Clinical Trial Application
Clinical Trial Design
Clinical Trial Registries
Clinical Trial Results
Clinical Trials
Cohort Study
Companion Diagnostics
Comparison Trials
Compassionate use
Compliance
Confirmatory Studies
Critical Review
Cross-Over Trial
Data Capture
Data Collection
Data monitoring committees
Data Protection
Demographics
Development Phases
Diagnosis
Digital Health Technologies
Distribution
Diversity
Documentary
Dosage
Dossier
Double Blind
Drug-Drug Interaction (DDI)
Early Clinical Development
Economic Evaluation
Education
Effectiveness Assessment
Efficacy
Elderly People
Eligibility
Endpoints
Engagement
Epidemiology
Epigenetics
Equal Access
Equity
Ethics
Ethnic Sub-groups
EUPATI
European Medicines Agency (EMA)
European Public Assessment Report (EPAR)
European Public Assessment Reports (EPARs)
Example of Patient Involvement
Excretion
First in Human
Food Effect
Galenic
Genotoxicity
Geriatric
Group Sequential Design
Guidance
Guidelines
Health Data
Health inequity
Health Policy
Health Systems
Health-related Quality of Life (HRQoL)
Healthcare Policy
Herbal Medicines
HIV
HTA
Hypothesis
Immunity
Impact Assessment
In Silico
In Vitro
In Vivo
Incidence
Informed Consent
Innovation
Lead Compound
Lead Generation
Lead Molecule
Lead Optimisation
Legislation
Levels of Evidence
Life-Cycle Management
Local Tolerance
Market Access
Marketing
Mass balance
Matched Pair
Measurement Bias
Medical Devices
Medical Technology
Medicine
Medicine Manufacturing
Medicines Discovery and Development
Medicines regulation
Metabolism
Mini-course
Multiple Sclerosis
Nanotechnology
Non-Clinical Testing
Off-Label
Open Label
Orphan Medicine
Paediatrics
Parallel-Import
Participants’ Rights
Patient
Patient Experience
Patient expert
Patient inclusion
Patient Information
Patient Involvement
Patient Organisations
Patient Participation
Patient Reported Outcome (PRO)
Patient Role In Digital Health
Patient Role In HTA
Patient story
Patient Training
Patient voice
Patient-Reported Outcome Measures (PROMs)
Patients Involved
Patients Involved Case Report
Patients’ Rights
Pediatric Research Equity Act (PREA)
Pediatrics
Periodic Safety Update Report (PSUR)
Personalised Medicine
Pharmacodynamics
Pharmacogenetics
Pharmacokinetics
Pharmacology
Pharmacopeidemiology
Pharmacopoeia
Pharmacovigilance
Pharmacovigilance Risk Assessment Committee (PRAC)
Phase I
Phase II
Phase III
Phase IV
Phytomedicine
Placebo
Populations
Post-Authorisation Efficacy Studies (PAES)
Post-Authorisation Safety Studies (PASS)
Pre-Clinical
Pre-Clinical Safety Studies
Pre-Clinical Testing
Pre-Discovery
Pregnancy
Premature termination
Prevalence
Prevention
Product Information
Prognosis
Proof of Concept
Proof of Mechanism
Proof of principle
Prospective Studies
Proteins
Protest
Protocol Design
Public Hearings
Public Involvement
Publication
Publication Bias
Qualitative Research
Quality Assurance
Quality Of Medicines
Quality Standards
Quantitative Research
Randomisation
Regulation
Reimbursement
Research
Research Priorities
Retrospective Studies
Risk
Risk Mitigation Strategies
Risk-Benefit
Safety
Sample Population
Screening
Seamless Phase II/Phase III Design
Selection Bias
Side Effects
Single Ascending Dose Escalation Study
Single Blind
Small Populations
Social Determinant
Special Populations
Stakeholders
Statistics
Stratification
Surrogate Endpoint
Symptoms
Target
Thorough QT
Toxicity
Toxicokinetics
Toxicology
Training
Translational Medicine
Treatment
Trial medicine
Triple Blind
Unauthorised Medicines
Unblinding
Vaccine
Withdrawal Trial
Find Out More
Toolbox
Guidance
Glossary
Creative Commons
Webinars
